louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03307031: The Influence of Pilates Exercises Training Volume on Metabolic Outcomes in Dyslipidemic Women.
Official title: The Influence of Pilates Exercises Training Volume on Metabolic, Physical Fitness and Quality of Life Outcomes in Dyslipidemic Women: A Controlled Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dyslipidemias
Keywords: training volume
elderly
lipid profile
postmenopausal
Lead sponsor: Federal University of Rio Grande do Sul
Sponsor class: OTHER
First posted: 2017-10-11
Enrollment: 26
Sex: FEMALE
Minimum age (years): 60
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A CONTROLLED CLINICAL TRIAL
Primary purpose: TREATMENT

Brief summary: The aim of the present study was to assess the influence of different volumes of Pilates training exercises on metabolic, blood pressure (BP), functional physical fitness (PF) and quality of life (QL) outcomes in postmenopausal dyslipidemic women. In total, 26 women participated in the controlled clinical trial, being allocated into three groups: high volume group (HVG; n=9), low volume group (LVG; n=11) and control group (CG, n=6). HVG performed four weekly sessions and LVG performed only twice a week, during 10 weeks with 45 to 55 minutes per session. Before and after the intervention period, metabolic, BP, PF, QL and cardiovascular risk score (CRS) outcomes were measured. The results were described by mean values with lower and upper limits (95% confidence interval). Comparisons between groups and intra-groups were performed adopting Generalized Estimating Equations (GEE) method, with post hoc of Bonferroni and significance level of ɑ=0,05.


Eligibility criteria: Inclusion Criteria:

* Dyslipidemic, postmenopausal and sedentary.

Exclusion Criteria:

* Women taking statins and smokers.

Primary outcomes:
measure: Metabolic outcomes
timeFrame: 10 weeks
measure: Metabolic outcomes
timeFrame: 10 weeks
measure: Metabolic outcomes
timeFrame: 10 weeks
measure: Metabolic outcomes
timeFrame: 10 weeks
measure: Metabolic outcomes
timeFrame: 10 weeks
Secondary outcomes:
measure: Secondary outcomes
timeFrame: 10 weeks
measure: Secondary outcomes
timeFrame: 10 weeks
measure: Secondary outcomes
timeFrame: 10 weeks
measure: Secondary outcomes
timeFrame: 10 weeks
Other outcomes:
Locations:
city: Porto Alegre
country: Brazil
facility: Adriana Cristine Koch Buttelli
state: Rio Grande do Sul
Study officials:
References:
Clinical trial NCT03171831: Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
Official title: Haploidentical Hematopoietic Stem Cell Transplantation for Patients With Thalassemia Major
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Thalassemia Major
Lead sponsor: First Affiliated Hospital of Guangxi Medical University
Sponsor class: OTHER
First posted: 2017-05-31
Enrollment: 30
Sex: ALL
Minimum age (years): 2
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to assess the safety and efficacy of haploidentical hematopoietic stem cell transplantation for patients with thalassemia major.

Detailed description: The only curative therapy for thalassemia major remains the replacement of the defective erythropoiesis by allogeneic hematopoietic stem cell transplantation(HSCT). However, this option is unavailable to many patients as a result of a lack of compatible donors.Haploidentical transplantation has been certified as a valuable alternative for hematological malignancy patients lacking a well-matched donor, with results comparable matched HLA-identical sibling donors or unrelated donors.The objective of this study is to test the feasibility of haploidentical HSCT for patients with thalassemia major.

Eligibility criteria: Inclusion Criteria:

1. Diagnosed with thalassemia major
2. Lacking of a HLA-identical sibling donor or unrelated donor
3. Indication of haploidentical hematopoietic stem cell transplantation
4. No restrictions for transplantation

Exclusion Criteria:

1. Any restriction for transplantation
2. No indication of haploidentical hematopoietic stem cell transplantation

Primary outcomes:
measure: Overall Survival
timeFrame: 2 years
Secondary outcomes:
measure: Disease Free Survival
timeFrame: 2 years
measure: Engraftment
timeFrame: 30 days
measure: Transplant Related Mortality
timeFrame: 1 year
measure: Cumulative Incidence of acute Graft Versus Host Disease
timeFrame: 180 days
measure: Cumulative Incidence of chronic Graft Versus Host Disease
timeFrame: 2 years
measure: Cumulative Incidence of Infectious Complications
timeFrame: 2 years
Other outcomes:
Locations:
city: Nanning
country: China
facility: First Affiliated Hospital of Guangxi Medical University
state: Guangxi
Study officials:
affiliation: First Affiliated Hospital of Guangxi Medical University
name: Yongrong Lai, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02573831: The Effect of Oxycodone to the Placental Circulation at Early Labour
Official title: The Effect of Oxycodone to the Placental Circulation at Early Labour
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Labor Pain
Keywords: labor
pain
oxycodone
placenta
Lead sponsor: Kuopio University Hospital
Sponsor class: OTHER
Collaborators: name: Admescope Ltd
First posted: 2015-10-12
Enrollment: 22
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Oxycodone is used to treat pain in early labor, however the effect of oxycodone to placental or fetal circulation has not been evaluated. Oxycodone is increasingly used to treat labor pain in the early phase. The aim of the randomised, double blinded, placebo controlled study was to evaluate the effects of oxycodone in placental circulation, efficacy and safety of oxycodone and the effects to the newborn.


Eligibility criteria: Inclusion Criteria:

* oxycodone planned for pain relief

  * age 18 years or more
  * Informed consent obtained
  * Full term pregnancy

Exclusion Criteria:

* No oxycodone planned

  * age less than 18 years
  * No informed consent
  * not full term pregnancy
* Other contraindication to oxycodone

Primary outcomes:
measure: placental blood flow
timeFrame: from zero hours to two hours after the first study drug
Secondary outcomes:
measure: uterine arterial flow
timeFrame: from zero hours to two hours after the first study drug
Other outcomes:
Locations:
city: Kuopio
country: Finland
facility: Kuopio University Hospital
state: Northern Savo
Study officials:
affiliation: Kuopio University Hospital
name: Merja Kokki, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00103831: Oral Taxane in Combination With Pemetrexed (Alimta) in Patients With Recurrent Non-Small Cell Lung Cancer
Official title: Phase I Alimta Combination With BMS-275183 (Oral Taxane)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Non-small Cell Lung Cancer
Keywords: NSCLC - non-small cell lung cancer
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2005-02-16
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Primary purpose: TREATMENT

Brief summary: A phase I-II dose ranging study of BMS-275183 (oral taxane) in combination with pemetrexed (Alimta) in patients with recurrent Non-Small Cell Lung Cancer (NSCLC). The safety and efficacy of this combination will be studied.


Eligibility criteria: Inclusion Criteria:

* Advanced or metastatic pretreated NSCLC
* Measurable disease
* Adequate hematologic, hepatic and renal functions.
* ECOG Performance Status 0-2

Exclusion Criteria:

* Inability to swallow capsules
* Recent significant cardiovascular disease
* Women who are pregnant or breastfeeding

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Denver
country: United States
facility: Local Institution
state: Colorado
city: Rochester
country: United States
facility: Local Institution
state: Minnesota
city: Toronto
country: Canada
facility: Local Institution
state: Ontario
Study officials:
References:
Clinical trial NCT01288131: Study of Anti-r-HuEpo Associated Pure Red Cell Aplasia (PRCA) Treatment
Official title: Randomized Controlled Trial Study of Anti-r-HuEpo Associated PRCA Treated by Cyclosporine and Mycophenolate Mofetil (MMF) Compared With Cyclophosphamide and Prednisolone
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Anti-r-HuEpo Associated PRCA Subjects
Keywords: Anti-r-HuEpo antibody
Anti-r-HuEpo associated PRCA
Treatment
Absolute reticulocyte count
Lead sponsor: Chulalongkorn University
Sponsor class: OTHER
First posted: 2011-02-02
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Recombinant human erythropoietin (r-HuEpo) has been used to treat renal anemia and improve morbidity and mortality in chronic kidney disease. Subcutaneous use of r-HuEpo causes immunogenicity and develops anti-r-HuEpo associated pure red cell aplasia (PRCA). The treatment of anti-r-HuEpo associated pure red cell aplasia is controversial. The investigators aim to evaluate the treatment for anti-r-HuEpo associated pure red cell aplasia in this study.

Detailed description: Recombinant human erythropoietin was the first biotherapeutic medicinal product derived from recombinant DNA technology for the treatment of anemia in patients with chronic kidney disease (CKD). Although r-HuEpo raises hemoglobin levels in CKD and improves morbidity associated with anemia in CKD patients, the adverse immunological effect of r-HuEpo administered subcutaneously can result in anti-r-HuEpo associated PRCA. We aim to evaluate the effectiveness of two treatment protocol, cyclosporine combined with mycophenolate mofetil and cyclophosphamide combined with prednisolone for treatment of anti-r-HuEpo associated PRCA.

Eligibility criteria: Inclusion Criteria:

* Age more than 18 years old
* CKD patient with anti-r-huEpo associated PRCA

Exclusion Criteria:

* Pregnancy or lactating women
* Receiving immunosuppression
* Active infection
* Previous history of allergic reaction to cyclosporine, mycophenolate mofetil, cyclophosphamide, prednisolone

Primary outcomes:
measure: anti-r-HuEpo antibody
timeFrame: Day 0 and month 6
Secondary outcomes:
measure: Absolute reticulocyte count
timeFrame: Day 0 and month 6
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Kearkiat Praditpornsilpa
Study officials:
affiliation: Chulalongkorn University
name: Kearkiat Praditpornsilpa, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01572831: PCT and Clinical Algorithm for Determination of Duration of Antibiotics
Official title: A Pilot Study to Evaluate a Procalcitonin-Based Algorithm for Duration of Antibiotic Therapy in Critically Ill Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Infection
Keywords: antibiotic cessation rules
procalcitonin
infection
critical care
Lead sponsor: Fraser Health
Sponsor class: OTHER
First posted: 2012-04-06
Enrollment: 1
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients in the ICU whose infection is resolving will be randomized to standard duration of antibiotics compared to duration determined by a combination of a procalcitonin value and a simple evaluation of clinical status.


Eligibility criteria: Inclusion Criteria:

* Adult patients (19 years and older) treated with ABx for reasons other than prophylaxis within the last 24 hours and who are admitted to a critical care environment.

Exclusion Criteria:

* Declined consent
* Any infection that according to evidence-based guidelines which would usually receive more than 2 weeks of antibiotic therapy including, but not limited to;

  * Infective endocarditis
  * Osteomyelitis
  * Undrained abscess
* Not expected to survive 48 hours
* Immunosuppression (HIV positive, any immunosuppressive medications, any steroid dose, neutrophil count less than 1.0)
* Previously enrolled in this study
* Presently enrolled in a separate study which is felt by study investigators to have biological or clinical process in conflict with this study.

Primary outcomes:
measure: Antibiotic- free days and alive at 14 days after ICU admission
timeFrame: 14 days
Secondary outcomes:
measure: mortality at 28 days
timeFrame: 28 days
measure: mortality at 90 days
timeFrame: 90 days
measure: ventilator days at 28 days
timeFrame: 28 days
measure: ICU free days at 28 days
timeFrame: 28 days
measure: relapsed infection
timeFrame: 30 days
measure: rates of CDAD
timeFrame: 30 days
measure: colonization/infection with VRE/MRSA over next 30 days
timeFrame: 30 days
measure: duration of abx in control arm for those with and without formal stewardship programs
timeFrame: 14 days
Other outcomes:
Locations:
city: New Westminster
country: Canada
facility: Royal Columbian Hospital
state: British Columbia
Study officials:
affiliation: University of British Columbia
name: Steven Reynolds, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03595631: Neurodynamic Interventions for Multiple Sclerosis
Official title: Effects of Neurodynamic Interventions to Multimodal Physical Therapy in Patients With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Multiple Sclerosis
Keywords: neurodynamics
pain
Lead sponsor: Universidad Rey Juan Carlos
Sponsor class: OTHER
First posted: 2018-07-23
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: A randomized, parallel-group, clinical trial will be conducted to compare the immediate effects of the inclusion of a neurodynamic intervention into a multimodal physiotherapy program on pressure pain sensitivity, pain and manual dexterity in patients with multiple sclerosis


Eligibility criteria: Inclusion Criteria:

* a diagnosis of multiple sclerosis according to the modified McDonald criteria;
* symptoms of paresthesia and lack of sensitivity in the upper extremity;
* Expanded Disability Status Scale (EDSS) between 0 and 6.5 points;
* absence of cognitive deficit.

Exclusion Criteria:

* any exacerbation of multiple sclerosis during the previous 3 months;
* previous hand surgery or steroid injections treatment in the upper extremity;
* multiple diagnoses on the upper extremity (e.g., cervical radiculopathy);
* cervical, shoulder, or upper extremity trauma;
* other comorbid musculoskeletal medical conditions;
* mini-mental state examination \<25

Primary outcomes:
measure: Changes in pressure pain sensitivity
timeFrame: Baseline and one week after the last treatment session
Secondary outcomes:
measure: Changes in upper extremity pain intensity before and after the intervention
timeFrame: Baseline and one week after the last treatment session
measure: Changes in light touch detection threshold
timeFrame: Baseline and after treatmentBaseline and one week after the last treatment session
measure: Changes in manual dexterity
timeFrame: Baseline and one week after the last treatment session
Other outcomes:
Locations:
city: Alcorcon
country: Spain
facility: César Fernández-de-las-Peñas
state: Madrid
Study officials:
References:
citation: de Dios Perez-Bruzon J, Fernandez-de-Las-Penas C, Cleland JA, Plaza-Manzano G, Ortega-Santiago R. Effects of neurodynamic interventions on pain sensitivity and function in patients with multiple sclerosis: a randomized clinical trial. Physiotherapy. 2022 Jun;115:36-45. doi: 10.1016/j.physio.2021.04.004. Epub 2021 Apr 22.
Clinical trial NCT06610331: EVALUATION OF THE EFFECT OF POLYVINYLPYROLIDONE AND SODIUM HYALURONATE GEL ON PALATINAL WOUND HEALING
Official title: EVALUATION OF THE EFFECT OF POLYVINYLPYROLIDONE AND SODIUM HYALURONATE GEL ON PALATINAL WOUND HEALING: A RANDOMIZED CONTROLLED CLINICAL STUDY
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Palatal Wound
Keywords: WOUND HEALİNG
sodium hyaluronate
Polyvinylpyrrolidone
Free gingival graft
PALATAL
Lead sponsor: Abant Izzet Baysal University
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 32
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this clinical study was to evaluate the effect of polyvinylpyrrolidone sodium hyaluronate gel on palatal wound healing, pain, and bleeding after free gingival graft surgery. This study included 32 systemically healthy patients who required free gingival graft surgery. After the operation, the test group received polyvinylpyrrolidone sodium hyaluronate gel in addition to chlorhexidine gluconate mouthwash, whereas the control group received only chlorhexidine gluconate mouthwash. VAS scale was used to evaluate palatal pain, burning, and chewing discomfort, WHI was used to evaluate wound healing, and H2O2 foaming test was used to evaluate epithelialization. VAS and bleeding values were recorded on postoperative day 1; VAS, WHI, H2O2, and bleeding values on postoperative days 3, 7, and 14; and WHI, H2O2, and bleeding values on postoperative day 28.


Eligibility criteria: Inclusion Criteria:

* Able to adapt to the study, not having a physical or psychological condition that would prevent surgical procedure under local anesthesia, and being able to follow the planned operation and control sessions
* Patients who consciously accept and sign the detailed informed consent form regarding the study that will be explained to them verbally
* Insufficiently attached gingiva on the mandibular or maxillary vestibular teeth and implant surfaces

Exclusion Criteria:

* Presence of infection and inflammation in the recipient and donor area
* Presence of systemic disease
* Women who are pregnant, suspected of being pregnant or breastfeeding
* Smoking
* Orofacial neurological symptoms

Primary outcomes:
measure: Epithelialization
timeFrame: 28 days
Secondary outcomes:
measure: wound healing
timeFrame: 28 days
Other outcomes:
Locations:
city: Bolu
country: Turkey
facility: Bolu Abant Izzet Baysal University Faculty of Dentistry Department of Periodontology
Study officials:
References:
Clinical trial NCT02348931: Clinical Effect of a Nasal Former in Nasal Deformities
Official title: Investigation of the Effect of a Customized Nasal Brace on Nasal Deformities With or Without Prior Surgery
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE3
Conditions: Nose Deformity
Lead sponsor: University of Zurich
Sponsor class: OTHER
First posted: 2015-01-28
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Investigation of the effect of customized nasal braces in the correction of nasal deformities with and without prior corrective surgery.

* Trial with medicinal product


Eligibility criteria: Inclusion criteria:

* Healthy adults with skewed, humped or broad nose, who are able to attend all follow-ups

Exclusion criteria:

* Inability to keep the research plan
* Allergies to components of the nasal brace
* Diseases of the bone metabolism
* Medication affecting bone metabolism
* Drugs or alcohol abuse

Primary outcomes:
measure: Skewed nose: Deviation from the 0° axis in the coronar plain (Philtrum-Glabella line).
timeFrame: 9 Weeks after surgery
measure: Humped nose: Deviation from the 0° axis in the sagittal plain (line from nose root to tip).
timeFrame: 9 Weeks after surgery
measure: Broad nose: Appealing proportion of nose width to eye-corner distance.
timeFrame: 9 weeks after surgery
measure: Skewed nose: Deviation from the 0° axis in the coronar plain (Philtrum-Glabella line).
timeFrame: 14 months of treatment with Nasella
measure: Humped nose: Deviation from the 0° axis in the sagittal plain (line from nose root to tip).
timeFrame: 14 months of treatment with Nasella
measure: Broad nose: Appealing proportion of nose width to eye-corner distance.
timeFrame: 14 months of treatment with Nasella
Secondary outcomes:
measure: Subjective Satisfaction
timeFrame: 9 weeks postoperatively
measure: Subjective Satisfaction
timeFrame: 14 months of treatment
measure: Doctors assessment of various appearances
timeFrame: 9 weeks postoperatively
measure: Doctors assessment of various appearances
timeFrame: 14 months after treatment
Other outcomes:
Locations:
city: Zurich
country: Switzerland
facility: University Hospital Zurich, Department of Otorhinolaryngology
state: ZH
Study officials:
affiliation: University Hospital Zurich, Department of Otorhinolaryngology
name: Thomas N Roth, Dr. med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06152731: HRD Tests for Ovarian cancER
Official title: HRD Tests for Ovarian cancER
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Ovarian Cancer
Keywords: HRD (Homologous Recombination Deficient)
GIScar
myChoice
platinum chemotherapy
Lead sponsor: Centre Francois Baclesse
Sponsor class: OTHER
First posted: 2023-12-01
Enrollment: 88
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The study concerns patients with Invasive epithelial ovarian cancer, primary Fallopian tube carcinoma, ovarian-type peritoneal carcinoma, and with an indication of a first-line platinum-based chemotherapy.

To determine HRD status, 2 separate tests will be performed in the study:

1. Giscar assay : developed by the sponsor
2. myChoice assay

If one or two tests identifies a HRD status :

a PARP inhibitor treatment may be initiated according to current recommendations


Eligibility criteria: Inclusion Criteria:

* Patient aged 18-year or more
* Histologically documented high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
* Newly diagnosed advanced (International Federation of Gynecology and Obstetrics \[FIGO\] stage III or IV) ovarian carcinoma, candidate to a first line platinum-based chemotherapy
* Tumor tissue must be available for HRD analyses (FFPE tissue block) and

  * Collected if possible during the initial surgery or the initial biopsy (before chemotherapy)
  * With sufficient tumour surface area (\> 25 mm²), with a final cellularity of at least 20%
* Patient affiliated to an appropriate social security system
* Patient signed consent form before any trial related activities

Exclusion Criteria:

* Recurrent high grade serous epithelial ovarian cancer, fallopian tube or peritoneum cancer
* Non epithelial or borderline ovarian cancer
* Other tumor, for which the treatment may interfere with the ovarian cancer treatment and/or that may have a major impact on prognosis
* Exclusive palliative setting
* Patient deprived of liberty or placed under the authority of a tutor

Primary outcomes:
measure: Rate of platinum-sensitive ovarian cancer patients according to GIScar HRD signature (classified into HRD or HRP).
timeFrame: six months after the end of platinum-based chemotherapy
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Chu Amiens
city: Caen
country: France
facility: Centre Francois Baclesse
city: Lille
country: France
facility: Centre Oscar Lambret
city: Rouen
country: France
facility: Centre Henri Becquerel
Study officials:
References: